Utama › Kanser Orofaring › Iowa
Kajian klinikal Kanser Orofaring di Iowa
5 kajian untuk Kanser Orofaring sedang mencari peserta di lokasi di Iowa.
Bandar di Iowa
Teks kajian rasmi (Bahasa Inggeris)
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
- UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic, Clive
- Iowa Methodist Medical Center, Des Moines
- dan 5 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Okt 2026 · NCT07195734BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Mary Greeley Medical Center, Ames
- McFarland Clinic - Ames, Ames
- UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
- dan 10 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05136196Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- McFarland Clinic - Ames, Ames
- UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
- Mercy Hospital, Cedar Rapids
- dan 8 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT06532279Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
- Mercy Hospital, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT07441681Integrated Cancer Repository for Cancer Research
- Methodist Jennie Edmundson Hospital, Council Bluffs
- Covenant Medical Center, Inc, Waterloo
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 19 hingga 110 · Semua jantina · Dikemas kini 29 Jun 2026 · NCT02012699Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.